/ /

Michelle Dalton
Topical squalamine a promising treatment for RVO-induced ME
Topical squalamine a promising treatment for RVO-induced ME
A proof-of-concept trial was launched to determine the safety and efficacy of squalamine lactate ophthalmic solution in eyes with macular edema secondary to branch and central retinal vein occlusion.
Exploring a new method for scleral buckling
A retinal surgeon describes a new scleral buckling device which requires less surgical dissection, has a one or two-stitch fixation, is applicable to treat pathology over 4 clock hours in any quadrant, and which can be removed in the office 3 to 4 weeks after insertion.
Using microscope-integrated intraoperative OCT in VR surgery
In the DISCOVER Study, ophthalmologists are exploring real-time, intraoperative optical coherence tomography utilizing a microscope-integrated prototype with a heads-up display surgeon feedback system.
Small-gauge PPV for vitreous floaters
James M. Osher, MD, identifies the patient characteristics and reviews some of the complications with small-gauge vitrectomy for vitreous floaters.
Managing pigment epithelial detachments with ranibizumab
Managing pigment epithelial detachments with ranibizumab
Large or small pigment epithelial detachments (PED) in neovascular age-related macular degeneration (AMD) can be managed effectively with ranibizumab PRN therapy with regular monitoring, said Rahul N. Khurana, MD.
Drug-delivery micropump for chronic retina disorders
A novel ophthalmic micropump system, implanted through minimally invasive surgery, is able to deliver the appropriate amount of drug needed at determined intervals, according to Mark S. Humayun, MD, PhD.
Round-the-clock IOP measurement becoming reality with technologic advances
The development of a device for 24-hour IOP monitoring is unique in that it can do so autonomously, without direct patient interaction, and can take measurements without external control signals.
Dexamethasone implant shows good safety, visual outcomes in MEAD study
Dexamethasone implant shows good safety, visual outcomes in MEAD study
Dexamethasone intravitreal implant 0.7 and 0.35 mg provided statistically and clinically significant improvement in best-corrected visual acuity and reduction in central subfield retinal thickness with an average of 4 to 5 injections over 3 years.
Latanoprostene bunod shows promise in patients with open-angle glaucoma, ocular hypertension
Findings from the CONSTELLATION study show that once-daily latanoprostene bunod lowered IOP more than twice-daily timolol in patients with open-angle glaucoma or ocular hypertension.
HARBOR results lead to ranibizumab label change
HARBOR results lead to ranibizumab label change
Findings from the HARBOR study on ranibizumab for wet macular degeneration prompted new labeling for a potentially less frequent than monthly dosing, depending on individual responses to treatments.

Poll

View Results